Page 6 - Celularity Inc News Today

Celularity Inc. (NASDAQ:CELUW – Get Free Report) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 8,900 shares, a drop of 11.9% from the June 15th total of 10,100 shares. Based on an average daily volume of 46,400 shares, the […]

NEW YORK, July 19, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty...

/PRNewswire/ -- The amniotic membrane market size is estimated to grow by USD 2,298.09 million at a CAGR of 14.6% between 2022 and 2027, according to Technavio....

Celularity Inc. (NASDAQ:CELU – Get Free Report) was the recipient of a large decrease in short interest during the month of June. As of June 30th, there was short interest totalling 1,560,000 shares, a decrease of 59.1% from the June 15th total of 3,810,000 shares. Based on an average daily trading volume, of 629,600 shares, […]

SAN DIEGO, July 12, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection...

Celularity Inc. (NASDAQ:CELU – Get Rating) was the target of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 3,390,000 shares, an increase of 10.8% from the May 15th total of 3,060,000 shares. Currently, 4.0% of the company’s shares are sold short. Based on […]

Celularity Inc. (NASDAQ:CELU – Get Rating) saw a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 3,390,000 shares, an increase of 10.8% from the May 15th total of 3,060,000 shares. Based on an average trading volume of 463,700 shares, the days-to-cover ratio is currently […]

Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout in allogeneic stromal cells leads to significantly lower tissue factor expression,... | June 1, 2023

Builds on Celularity's December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and clinical and investigational stage cellular therapeutic programsMarks

Builds on Celularity’s December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and clinical and investigational...